WellPrept
Decision Aid

Does medication go in the bladder after TURBT?

You have non-muscle-invasive bladder cancer, and the tumor has been removed. Your urologist will talk with you about whether medication goes in the bladder next, and which one. This page lays the four choices out side by side.

Last reviewed 2026-06-05 Reading time ~8 min Print-friendly
A note before you start

This tool does not pick for you. Your urologist sorts your cancer into a risk group, and that risk group decides which options you have.

Bladder cancer that has not reached the muscle is sorted into low, intermediate, or high risk based on the size, number, grade, and stage of your tumor. Your risk group decides which of the options below apply to you. Read this page after your urologist has told you your risk group. If you have not been told yet, ask. For the full picture of the disease, read the bladder cancer (NMIBC) patient guide.

Chapter 1 · The decision

What this decision is about

Your tumor was taken out during a procedure called TURBT (transurethral resection of bladder tumor). Medication can go into the bladder afterward, through a small tube, to lower the chance the cancer comes back.

Medicine put straight into the bladder is called intravesical therapy. A thin catheter goes through the urethra. The medicine sits in the bladder for one to two hours and then is voided out. The medicine touches the lining where bladder cancer starts and stays mostly inside the bladder.

There are four paths after TURBT.

  • Surveillance only. Nothing more in the bladder. Follow-up cystoscopy on a set schedule to look for the cancer coming back.
  • One dose of chemotherapy in the bladder right after TURBT. Mitomycin or gemcitabine. A single instillation in the first 24 hours.
  • Bacillus Calmette-Guerin (BCG). A weakened bacterium put in the bladder. You get six weekly doses (induction), and then maintenance doses over one to three years.
  • Gemcitabine and docetaxel (Gem/Doce). Two chemotherapy medicines given one after the other into the bladder, in induction and maintenance. Used during BCG shortages and when BCG is not the right fit.

A fifth option, removing the bladder (radical cystectomy), is used in some of the highest-risk cases, but it is a different decision with its own aid.

What your urologist brings to the choice

Your urologist will tell you your risk group. That judgment weighs how many tumors there were, how big, what grade, whether any flat carcinoma in situ (CIS) was found, and whether this is your first bladder cancer or a return. Your urologist also knows what BCG supply looks like in your area right now, and will factor in your other medical conditions, your ability to come in for repeat instillations, and how you do with side effects. From all of that, they will tell you which options on this page fit your situation and which do not. This page is for after that talk.

Chapter 2 · Your options

Compare the four paths

The columns sit side by side in no particular order of preference. Reading down a column tells you about one option, and reading across a row compares all four on a single point. Not every option fits every risk group, and the last row says who each option fits.

Option 1Surveillance only Option 2Single dose of chemotherapy after TURBT Option 3BCG (induction plus maintenance) Option 4Gem/Doce (induction plus maintenance)
What it is No medicine in the bladder after TURBT. Follow-up looks for the cancer coming back so it can be caught early and treated. One dose of mitomycin or gemcitabine put into the bladder through a catheter within 24 hours of the TURBT. Held for one to two hours, then voided. A weakened germ related to the tuberculosis vaccine. Put into the bladder once a week for six weeks (induction). If it works, more rounds of three weekly doses follow at set times over one to three years (maintenance). Gemcitabine put into the bladder for one to two hours, voided, then docetaxel put in for one to two hours, on the same day. Six weekly doses (induction), then maintenance every few months.
How it works Cystoscopy looks inside the bladder. Urine cytology checks the urine for cancer cells. If something new shows up, it is biopsied or resected. The medicine kills any stray cancer cells floating in the bladder right after surgery, before they can stick to the lining. BCG triggers a strong immune response inside the bladder. The body's own immune cells attack the bladder lining and any cancer cells there. Two chemotherapy medicines with different ways of killing cancer cells, given back to back to hit the lining harder than either one alone.
Setting and schedule Office cystoscopy every 3, 6, or 12 months depending on your risk group. No instillations. One visit in the recovery area or office within 24 hours of TURBT. Just that one dose. Outpatient visits to the urologist's office. Six weekly visits, then short maintenance courses (three weekly doses) at 3, 6, 12, 18, 24, 30, and 36 months in the standard schedule. Outpatient visits. Six weekly visits for induction, then maintenance instillations on a set schedule, often monthly for several months, then less often.
How well it works For low-risk bladder cancer (small, solitary, low-grade Ta), the cancer comes back in about 30 to 40 out of 100 people over five years, but it almost never reaches the muscle layer. Adding this one dose cuts the early recurrence rate by about 35 to 40% compared with TURBT alone in low and intermediate risk. The standard for intermediate and high risk for more than 40 years. With maintenance, lowers both recurrence and the chance the cancer moves into deeper layers. For high-grade non-muscle-invasive disease, a large multi-center study reported about 92 out of 100 people free of high-grade recurrence at 6 months with Gem/Doce, compared with about 76 out of 100 with BCG. At 2 years, 81 out of 100 with Gem/Doce and 69 out of 100 with BCG. These are early data and not yet from a head-to-head trial.
Side effects in the days after a dose None from medicine. Cystoscopy can cause one or two days of burning when you urinate. Burning, frequency, blood in urine for a day or two. Skin rash on the lower belly or hands if mitomycin touches skin. Burning, frequency, urgency for one to two days. Low-grade fever, fatigue, body aches. Less common: high fever, persistent bladder pain, prostate or testicle inflammation. Rare: a body-wide BCG infection that needs hospital treatment. Burning, frequency, urgency for one to two days, similar to BCG but generally less intense. In a comparative cohort, adverse events were 40 out of 100 with Gem/Doce versus 74 out of 100 with BCG.
Time commitment over the next 3 years Cystoscopy visits only. For low risk, perhaps 4 to 6 visits in 3 years. For higher risk on surveillance, more. One extra visit beyond the surveillance schedule. Six visits in the first six weeks, then three visits at each of seven maintenance points. About 27 instillation visits over 3 years, on top of cystoscopy. Six visits in the first six weeks, then maintenance visits on a set schedule. Roughly similar to BCG in total visits, sometimes fewer.
Cost in the United States Lowest medicine cost (none). Cystoscopy and urine tests at each visit, usually covered by insurance. Low one-time medicine cost. Usually covered. The BCG medicine itself is inexpensive when supply is available. Office visits and instillation are usually covered. Out-of-pocket cost depends on your plan. Gemcitabine and docetaxel together cost more per dose than BCG. Most plans cover them when BCG is in short supply, but coverage rules and prior authorization vary.
Effect on the bladder over time None from treatment. The bladder is the same after surveillance visits. Almost none after the one dose. Years of BCG can leave the bladder smaller, stiffer, or more sensitive in a minority of people. Bladder symptoms between doses can build up. Less well studied long-term than BCG, but early data suggest fewer lasting bladder symptoms.
What it does NOT do Does not lower the chance of recurrence. Catches recurrences early. Does not replace BCG or Gem/Doce in intermediate or high risk. Does not lower the chance of cancer reaching the muscle. Does not eliminate recurrence; it lowers the odds. Does not work for every patient; some cancers come back despite BCG. Does not have decades of follow-up data the way BCG does. Long-term outcomes are still being studied.
Best fit when… Your cancer is low risk: one small, low-grade Ta tumor, no CIS, no prior bladder cancer. Talk with your urologist about whether the single post-TURBT dose still adds value in your case. Your cancer is low or intermediate risk, the TURBT was clean (no perforation, not too much bleeding), and you can receive it within 24 hours. Often given on top of, not instead of, longer treatment in intermediate risk. Your cancer is intermediate or high risk, including high-grade Ta, T1, or CIS. BCG is an option whenever supply is available and you can tolerate it. Your cancer is intermediate or high risk and BCG is not available locally, or BCG has not worked for you, or you cannot tolerate BCG. Increasingly used as first-line in some centers during the ongoing BCG shortage.
When to reconsider If a new tumor is found on cystoscopy, the choice opens back up. The new tumor may move you into a higher risk group. If your risk group is intermediate or high, you and your urologist will talk about adding induction and maintenance therapy after the single dose. If BCG is not available locally, if side effects are too much, or if the cancer comes back during or after BCG. Talk with your urologist about Gem/Doce, other options, or in some cases removing the bladder. If the cancer comes back during or after Gem/Doce, your urologist will talk with you about switching to BCG (if available), other intravesical options, FDA-approved bladder-preserving treatments for BCG-unresponsive disease, or removing the bladder.

A note on newer options if BCG does not work

If you have already had BCG and the cancer came back in a defined way (this is called BCG-unresponsive disease), the options change. Three medicines have been FDA-approved since 2020 for that situation: pembrolizumab (an IV immune medicine), nadofaragene firadenovec (a gene therapy put in the bladder every three months), and nogapendekin alfa inbakicept given with BCG. Removing the bladder is also an option. Ask your urologist which of these fit your case.

Chapter 3 · The honest disagreements

Where urologists disagree

Two thoughtful urologists can look at the same case and pick a different path. These are the points where they differ:

  • BCG or Gem/Doce as the first choice during the shortage. BCG has more than four decades of data behind it and remains the long-standing reference for intermediate and high-risk disease. Gem/Doce is newer, has shorter follow-up, and has shown strong early results in large studies. With BCG hard to get in many parts of the United States, some urologists now start with Gem/Doce for intermediate-risk and even some high-risk cases. Others hold BCG as the first choice whenever they can get it. Both views are defensible. What your urologist offers may depend on what is in stock in your area this month.
  • How long to keep going with maintenance BCG. The classic schedule runs out to three years. Some urologists shorten it to one year for intermediate-risk patients, citing patient tolerance and the cost of three years of regular instillations. Others stick with the full three years, citing the evidence that longer maintenance lowers recurrence further. Both are reasonable. Your tolerance for side effects and how the first year goes both feed this conversation.
  • The single post-TURBT dose for everyone, or just some? Older guidelines pushed the one-time dose within 24 hours of TURBT for nearly every low and intermediate-risk patient. Some urologists still do that. Others give it only when the recurrence risk profile fits well and the TURBT went smoothly. The dose adds little time but is not free of side effects. Ask why your urologist did or did not offer it for your TURBT.

If you are weighing these options, ask your urologist which they pick and why for your case. For high-risk disease, consider a second opinion at a center that handles a lot of bladder cancer. The same goes for any decision that swaps BCG for Gem/Doce or moves toward removing the bladder.

How the BCG shortage changes your options

BCG supply in the United States has been intermittently short since about 2012, with one FDA-approved manufacturer. Many urology practices ration BCG, sometimes splitting one vial across more than one patient (this is called split-dose BCG and works well in most situations). If your urologist offers split-dose BCG or Gem/Doce instead of standard-dose BCG, they are adapting to a supply problem outside their control. It says nothing about your case.

Chapter 4 · Your trade-offs

What you are weighing

Your risk group decides which options are open to you. As you read the comparison, ask yourself:

  • What risk group did my urologist put my cancer in? Have they explained why?
  • How much do the regular visits matter to me? Can I get to the office once a week for six weeks, then on the maintenance schedule for years?
  • How well do I usually tolerate side effects? Have I had a rough time with bladder symptoms before?
  • Do I have other conditions that change what is safe for me (active urinary infection, immune problems, a history of tuberculosis)?
  • If BCG is not available locally right now, am I willing to start with Gem/Doce, or would I rather wait?
  • How will I keep track of cystoscopy appointments over the next several years? Surveillance is a long-term commitment regardless of which option I pick.
  • If the cancer comes back, what is our plan? Am I clear on what comes next?
  • How will my partner, family, or caregiver be part of this? Can they help with the visits and the follow-up schedule?
The week before each cystoscopy

Many bladder cancer patients say the week before a follow-up cystoscopy is the hardest week of the cycle, especially in the first two years. That feeling is common, and it has a name: scanxiety. If it gets in the way of daily life, tell your urologist's office. Support groups through the Bladder Cancer Advocacy Network (BCAN) and brief mental health support both help.

Chapter 5 · Take these to your appointment

Good questions to ask your urologist

Print this page or write these down. The space at the bottom is for your own questions.

About my cancer

  1. What risk group is my cancer in: low, intermediate, or high? What made you place it there?
  2. Is there any CIS on my pathology report? Was muscle in the specimen so we know the depth for sure?
  3. Do I need a second TURBT in the next 4 to 6 weeks?

About the choice in front of me

  1. Given my risk group, which options on this page apply to me, and which do not?
  2. If BCG is an option for me, do you have it available in this practice right now? If not, what is the wait, and what would you do in the meantime?
  3. If BCG is not available, would you start me on Gem/Doce instead, or do you have another plan?
  4. If I go with BCG, do you plan to use split-dose BCG? What does that mean for my treatment?
  5. How long do you plan to keep me on maintenance, and why that length?

About the long road

  1. What is my cystoscopy schedule going to look like over the next 1, 3, and 5 years?
  2. If the cancer comes back during treatment, what is our next step? Will we change medicines, or talk about removing the bladder?
  3. If I have side effects between doses that worry me, who do I call, and when should I worry?
  4. Should I be quitting smoking now? Where can you refer me for help?

My own questions:

Where this information comes from

  1. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer, 2025 edition. Sections on risk stratification, intravesical chemotherapy, BCG induction and maintenance, and BCG-unresponsive disease.
  2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Bladder Cancer, current version. Sections on NMIBC risk groups and intravesical therapy.
  3. Steinberg RL, Thomas LJ, O'Donnell MA, et al. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer, peer-reviewed cohort series.
  4. McElree IM, Steinberg RL, Mott SL, et al. Comparative effectiveness of sequential intravesical gemcitabine and docetaxel versus BCG in BCG-naive patients with non-muscle-invasive bladder cancer. JAMA Network Open multicenter cohort.
  5. Lamm DL, Blumenstein BA, Crissman JD, et al. SWOG 8507: maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1, and carcinoma in situ transitional cell carcinoma of the bladder. Foundational maintenance BCG schedule trial.
  6. Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057). Lancet Oncology phase 2 trial.
  7. Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: 5-year follow-up of a phase 3 trial.
  8. Bladder Cancer Advocacy Network (BCAN) patient resources, including the BCG shortage explainer.
This decision aid does not recommend one option over another. Outcome numbers reflect typical published ranges; your risk group, your local BCG supply, your other medical conditions, and how you tolerate treatment may make some options more or less appropriate. Your urologist is the right person to translate this material to your situation.

WellPrept Decision Aid · nmibc-intravesical-therapy-choice · v1 · next review 2027-06-05